Compare ASML Holding NV (ASML) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASML Holding NV vs Bristol-Myers Squibb Co — how do they compare? ASML Holding NV trades at $1,819.04 (market cap $689.17B), while Bristol-Myers Squibb Co trades at $63.81 (market cap $129.94B). The key difference: ASML Holding NV is far larger — about 5.3× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| ASML | BMY | |
|---|---|---|
Market Cap | $689.17B | $129.94B |
Sector | Technology | Health |
52-Week High | $1.99K | $65.89 |
52-Week Low | $725.85 | $42.60 |
Enterprise Value | $682.70B | $163.92B |
Dividend Yield | 0.5% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASML trades at $1,733.48, down 0.43% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a 29.41% net income margin and robust revenue growth to $32.67B in 2025. Recent earnings beats in Q1 and Q2 2026, coupled with a consensus price target of $2,390, highlight positive momentum, though high valuation ratios like a P/E of 61.28 pose risks.
Outlook remains favorable due to AI-driven semiconductor demand, but investors face risks from geopolitical tensions with China and stretched valuations. Analyst consensus is strongly bullish with 57% buy ratings, supporting potential upside, though monitoring competitive threats and earnings consistency is crucial for sustained growth.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASML Holding NV
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
